Full Press Release Details
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to
Equity; On Track to Regain Nasdaq Compliance by August 23
JERUSALEM, Aug. 15, 2024 /PRNewswire/ -- Scinai
Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused
on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices
business unit, today published its financial results for the quarter ended June 30, 2024 and provided a business update. The Company will
hold a webinar covering its Q2 2024 financial results and business update on August 20th at 11AM EDT/18:00 Israel time.
Registration for the webinar can be done using the following LINK.
Business Update & Recent Highlights
Conversion of EIB Loan into Equity and Regaining Nasdaq Compliance
On June 7, 2024, the Company announced that on June 5, 2024, it had
received formal notification from the Listing Qualification Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq")
that the Company remains non-compliant with the requirement in Listing Rule 5550(b)(1) that a company have stockholders' equity of at
least $2.5 million, or any of the alternative requirements under Nasdaq Listing Rule 5550(b) ("Equity Requirement"). Accordingly,
on June 18, 2024, the Company presented its plan to regain compliance with the Equity Requirement with the Nasdaq Hearing Panel. The plan
presented to the panel included a debt-to-equity loan restructuring deal between the Company and the European Investment Bank (the "EIB").
On July 3, 2024, the Company announced that the Hearings Panel had
determined to grant the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions,
including filing on or before August 14, 2024 a public disclosure demonstrating compliance with the Equity Requirement.
On August 13, 2024, the Company announced that it had signed a Loan
Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract with the EIB. The closing of the
transaction is subject to delivery of customary closing documents and is expected to close by August 23, 2024. In connection with the
transaction, an amount equal to approximately EUR 26.6 million (equal to approximately $29 million), including interest accrued
to date, owed by the Company to the EIB under the amended Finance Contract between the parties will be converted into 1,000 preferred
shares, no par value per share, of the Company (the "Preferred Shares") convertible into ADSs. Following such conversion, the
total outstanding amount owed by the Company to the EIB will be EUR 250,000 (equal to approximately $273,000). The outstanding amount
will have a maturity date of December 31, 2031, will not be prepayable in advance, and no interest accrues or is due and payable
on such amount. Under the terms of the agreement, EIB may not convert its Preferred Shares into ADSs for a period of twelve (12)
months from the date of issuance of the Preferred Shares. In addition, EIB may not convert its Preferred Shares into ADSs if at
the time of conversion the aggregate number of ADSs EIB will receive or would have been entitled to receive within the twelve months prior
to such conversion would exceed 4.99% of the ADSs issued and outstanding at the time of such conversion.
On August 14, 2024h the Company received from the Nasdaq
Hearing Panel an extension until August 23, 2024 to close the restructuring transaction with the EIB and thereby demonstrate compliance
with the Equity Requirement. Following closing of the restructuring transaction with the EIB, the Company intends to issue a press release
submitted on Form 6-K stating that as a result of the completed loan restructuring, the Company has stockholders' equity above $2.5 million
as of the date of the filing. .
Since Jan 2024, the Company has received CDMO work orders valued at
approximately $600K, and the Company is in advanced contract discussions with several other potential clients. The Company maintains confidence
in its sales guidance for 2024 of $1.25 million in expected revenues. As the Company CDMO unit is new, and the Company is focused
on rapidly growing, acquiring new clients and building its reputation and brand awareness of its CDMO services, the Company expects revenues
from the CDMO business to increase materially in the coming years. This is also coupled with growing demand for boutique CDMO services
from early-stage biotech companies looking for fast project onset at competitive pricing without compromising on meeting the most stringent
scientific and quality standards.
In addition, in 2024 the Company has been pursuing extensive targeted
marketing activities, including online advertisements, direct outreach campaigns and participation in major pharmaceutical conferences,
such as BIO Europe Spring in Barcelona (March 2024), and the BioMed Israel conference in Tel Aviv, Israel (May 2024), at which the Company
marketed its CDMO services and met potential partners for its R&D pipeline and potential investors.
The Company's CDMO unit is currently focused both on executing drug
development projects for its clients and on validating its processes and facilities to be ready for cGMP inspection by the Israeli Ministry
In June 2024, the Company held its first of its kind, hands on aseptic
processing course at its facility in Jerusalem in collaboration with key figures in the industry including Ms. Rachel Shimonovitz, Head
of GMP inspectorate of the Israeli Ministry of Health, and ADRES Int'l Biotech, a leading Israeli regulatory and quality consulting services
firm. The course attracted many senior role holders from the Israeli biotech industry who came to the Company's facility for this two-day
education and training course.
Pipeline Development
The Company is aggressively advancing the NanoAb preclinical development.
At the end of April 2024, the Company concluded an in-vivo proof of concept animal study in collaboration with Prof. Amos Gilhar, a world-renowned
dermatologist of the prestigious Technion Israel Institute of Technology.
On July 15, 2024, the Company announced promising results as the statistical
analysis of psoriasis markers measured in the study confirmed that the effect of Scinai's NanoAb was similar to that of the two comparator
drugs, supporting the hypothesis that intralesional injection of a nanoAb blocking the IL-17 cytokine can positively impact the inflammatory
cytokine cascade, and lead to reduction in psoriatic lesion severity and improvement of the skin's integrity. By delivering a biological
treatment directly into psoriatic lesions, the Company aims to improve disease management for patients suffering from mild to moderate
plaque psoriasis by offering the high potency and specificity advantages reserved for biologic drugs while providing a safer and more
convenient treatment option compared to existing therapies currently offered to this patient category.
On June 4, 2024, the Company met for a scientific advisory meeting
with the Paul Erlich Institute (the PEI) of Germany, the scientific advice of which is considered acceptable guidance for IMPD filing
with the European Medicines Agency (EMA) and is also considered the European comparable to a pre-IND meeting with the FDA in the U.S.
Consequently, on July 23, 2024, the Company announced the receipt of
positive regulatory feedback from the PEI for its drug development program towards Phase 1/2a clinical trial of its anti-IL-17A/F nanoAb
(SCN-1) in Plaque Psoriasis. The minutes of meeting clarified its preclinical toxicology and clinical program for Plaque Psoriasis with
intralesional injections for the treatment of patients with mild to moderate Plaque Psoriasis. The PEI requested to see data of efficacy
in blocking IL-17F, and this data became available as per the Company's announcement on July 15, 2024 describing the positive in vivo
proof of concept results. The PEI accepted the Company's position that toxicology studies can be conducted in pigs rather than in Non-Human
Primates. The PEI also accepted the Company's position to compare the SCN-1 to placebo directly in patients with mild to moderate plaque
psoriasis while skipping the need for testing in healthy volunteers, resulting in a phase 1/2a clinical trial, which will assess both
safety and efficacy in the same trial. Moreover, the PEI agreed to compare SCN-1 to placebo on the same human subject, a strategy that
could significantly reduce the number of patients required for the clinical trial. Last, the PEI commented that the manufacturing process
looks well developed and that controls and specifications presented are acceptable.
The Phase 1/2a study is expected to include approximately 24 plaque
psoriasis patients and is expected to commence in the second half of 2025 with readout in 2026.
Additional NanoAbs for treatment of additional autoimmune diseases,
such as asthma, atopic dermatitis and wet AMD, have been discovered and characterized at Max Planck and University Medical Center G ttingen
as part of their research collaboration agreement with Scinai. Scinai holds exclusive options for exclusive licenses at pre-agreed financial
terms for each of the resulting NanoAbs.
The Company is pursuing strategic partnerships and sublicensing options
for both its COVID-19 self-administered inhaled NanoAb, which demonstrated highly promising in vivo results in animals as both a therapeutic
and prophylactic treatment, and its anti-IL-17 nanoAb for the treatment of plaque psoriasis and other potential indications.
Q2 2024 Financial Summary
As of June 30, 2024, the Company had cash and cash equivalents
and short-term deposits of $3,076 thousands compared to $4,870 thousands as of June 30, 2023.
U.S. dollars in thousands
| June 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 3,076 | $ | 4,870 | ||||
| Restricted cash | 138 | 140 | ||||||
| Trade receivables | 119 | - | ||||||
| Prepaid expenses and other receivables | 324 | 437 | ||||||
| Total current assets | 3,657 | 5,447 | ||||||
| NON-CURRENT ASSETS: | ||||||||
| Property, plant and equipment, net | 10,180 | 10,825 | ||||||
| Operating lease right-of-use assets | 1,014 | 1,200 | ||||||
| Total non-current assets | 11,194 | 12,025 | ||||||
| Total assets | $ | 14,851 | $ | 17,472 |
The accompanying notes are an integral part of the financial statements.
U.S. dollars in thousands (except share data)
| June 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| LIABILITIES NET OF CAPITAL DEFICIENCY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 658 | $ | 535 | ||||
| Operating lease liabilities | 364 | 396 | ||||||
| Other payables | 650 | 849 | ||||||
| Total current liabilities | 1,672 | 1,780 | ||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Warrants liability | 3 | 96 | ||||||
| Loan from others | 19,820 | 19,368 | ||||||
| Non-current operating lease liabilities | 640 | 797 | ||||||
| Total non-current liabilities | 20,463 | 20,261 | ||||||
| SHAREHOLDERS' DEFICIT: | ||||||||
| Ordinary shares of no par value: Authorized: 20,000,000,000 shares at June 30, 2024 and at December 31, 2023; Issued and outstanding 3,349,431,584 shares at June 30, 2024 and 1,857,169,984 shares at December 31, 2023 | - | - | ||||||
| Additional paid-in capital | 121,272 | 119,506 | ||||||
| Accumulated deficit | (126,816 | ) | (122,335 | ) | ||||
| Accumulated other comprehensive loss | (1,740 | ) | (1,740 | ) | ||||
| Total shareholders' deficit | (7,284 | ) | (4,569 | ) | ||||
| Total liabilities and shareholders' deficit | $ | 14,851 | $ | 17,472 |
The accompanying notes are an integral part of the financial statements.
STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share data)
| For the six months ended June 30 | ||||||||
| 2024 | 2023 | |||||||
| Revenues | $ | 284 | $ | - | ||||
| Cost of revenues | 448 | - | ||||||
| Gross loss | (164 | ) | - | |||||
| Research and development expenses, net | $ | 2,788 | $ | 3,449 | ||||
| Marketing, general, and administrative expenses | 1,003 | 2,332 | ||||||
| Total operating expenses | 3,791 | 5,781 | ||||||
| Total operating loss | 3,955 | 5,781 | ||||||
| Total Financial Expenses net, | 526 | 1,496 | ||||||
| Net loss | $ | 4,481 | $ | 7,277 | ||||
| Net loss per share attributable to ordinary shareholders, basic and diluted | (0.002 | ) | (0.006 | ) | ||||
| Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted | 2,288,278,248 | 1,322,019,241 |